PREDICT与Adjuvant!在线预后工具对50岁以下早期乳腺癌患者的准确性
该医院队列纳入1990至2000年诊断的2710例50岁以下单侧I-III期乳腺癌患者,评估PREDICT和Adjuvant!对10年全因死亡和乳腺癌特异性死亡的校准与区分度。PREDICT全因死亡校准良好(平均差-1.1%),但高估乳腺癌特异性死亡3.2%;区分度中等至良好(C统计量0.71)。Adjuvant!结果与PREDICT相似。作者认为预后工具应谨慎使用,因估计值存在内在变异且辅助全身治疗讨论阈值低。
要点
- PREDICT对50岁以下乳腺癌患者10年全因死亡校准良好,平均差-1.1%(95%CI:-3.2%-0.9%;P=0.28)。
- PREDICT高估乳腺癌特异性死亡3.2%(95%CI:0.8%-5.6%;P=0.007),且在多个亚组中似无差别高估(平均差范围3.2%-14.1%)。
- PREDICT全因死亡区分度中等至良好(C统计量0.71,95%CI:0.68-0.73),Adjuvant!结果与PREDICT相似。
核心结论
- PREDICT对50岁以下乳腺癌患者10年全因死亡的估计似乎合理,尽管在极端值处不精确;Adjuvant!结果相似。
- 由于预后工具估计值存在内在变异,且讨论辅助全身治疗的阈值低,看似不显著的几个百分点死亡高估或低估可显著影响治疗决策,因此应谨慎使用。
研究设计与样本
- 医院为基础的队列研究,纳入1990至2000年间诊断的2710例既往无癌症史的50岁以下单侧I-III期乳腺癌连续病例。
- 主要结局指标为估计10年全因死亡和乳腺癌特异性死亡的校准与区分度(以C统计量衡量)。
主要发现
- PREDICT全因死亡校准良好,预测与观察平均差-1.1%(95%CI:-3.2%-0.9%;P=0.28)。
- PREDICT在良好预后亚组中倾向于低估全因死亡(平均差范围-2.9%至-4.8%),在不良预后亚组中高估全因死亡(平均差范围2.6%至9.4%),在小于35岁患者中低估生存-6.6%。
- PREDICT高估乳腺癌特异性死亡3.2%(95%CI:0.8%-5.6%;P=0.007),且在众多亚组中似无差别高估(平均差范围3.2%至14.1%)。
- 在死亡概率最低和最高的患者队列中校准较差。
- PREDICT全因死亡区分度中等至良好(C统计量0.71,95%CI:0.68-0.73),乳腺癌特异性死亡结果相似;Adjuvant!对全因死亡和乳腺癌特异性死亡的校准与区分度结果与PREDICT一致。
关键数值与推荐
- PREDICT全因死亡预测与观察平均差-1.1%(95%CI:-3.2%-0.9%;P=0.28)。
- PREDICT良好预后亚组全因死亡平均差范围-2.9%至-4.8%,不良预后亚组平均差范围2.6%至9.4%,小于35岁患者低估生存-6.6%。
- PREDICT乳腺癌特异性死亡高估3.2%(95%CI:0.8%-5.6%;P=0.007),亚组平均差范围3.2%至14.1%。
- PREDICT全因死亡C统计量0.71(95%CI:0.68-0.73)。
临床怎么用
- 作者认为,PREDICT对50岁以下乳腺癌患者10年全因死亡的估计似乎合理,但预后工具应谨慎使用,因估计值存在内在变异且辅助全身治疗讨论阈值低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Online prognostication tools such as PREDICT and Adjuvant! are increasingly used in clinical practice by oncologists to inform patients and guide treatment decisions about adjuvant systemic therapy. However, their validity for young breast cancer patients is debated. OBJECTIVE: To assess first, the prognostic accuracy of PREDICT's and Adjuvant! 10-year all-cause mortality, and second, its breast cancer-specific mortality estimates, in a large cohort of breast cancer patients diagnosed <50 years. DESIGN: Hospital-based cohort. SETTING: General and cancer hospitals. PARTICIPANTS: A consecutive series of 2710 patients without a prior history of cancer, diagnosed between 1990 and 2000 with unilateral stage I-III breast cancer aged <50 years. MAIN OUTCOME MEASURES: Calibration and discriminatory accuracy, measured with C-statistics, of estimated 10-year all-cause and breast cancer-specific mortality. RESULTS: Overall, PREDICT's calibration for all-cause mortality was good (predicted versus observed) meandifference: -1.1% (95%CI: -3.2%-0.9%; P = 0.28). PREDICT tended to underestimate all-cause mortality in good prognosis subgroups (range meandifference: -2.9% to -4.8%), overestimated all-cause mortality in poor prognosis subgroups (range meandifference: 2.6%-9.4%) and underestimated survival in patients < 35 by -6.6%. Overall, PREDICT overestimated breast cancer-specific mortality by 3.2% (95%CI: 0.8%-5.6%; P = 0.007); and also overestimated it seemingly indiscriminately in numerous subgroups (range meandifference: 3.2%-14.1%). Calibration was poor in the cohort of patients with the lowest and those with the highest mortality probabilities. Discriminatory accuracy was moderate-to-good for all-cause mortality in PREDICT (0.71 [95%CI: 0.68 to 0.73]), and the results were similar for breast cancer-specific mortality. Adjuvant!'s calibration and discriminatory accuracy for both all-cause and breast cancer-specific mortality were in line with PREDICT's findings. CONCLUSIONS: Although imprecise at the extremes, PREDICT's estimates of 10-year all-cause mortality seem reasonably sound for breast cancer patients <50 years; Adjuvant! findings were similar. Prognostication tools should be used with caution due to the intrinsic variability of their estimates, and because the threshold to discuss adjuvant systemic treatment is low. Thus, seemingly insignificant mortality overestimations or underestimations of a few percentages can significantly impact treatment decision-making.
引用
- Engelhardt EG, van den Broek AJ, Linn SC, et al. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. Eur J Cancer. 2017. PMID: 28412587. doi:10.1016/j.ejca.2017.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。